Rat Monoclonal Cmtm6 Antibody

Cmtm6 (CKLF-like MARVEL transmembrane domain-containing 6) is a protein involved in regulating the stability and membrane localization of programmed death-ligand 1 (PD-L1), a key immune checkpoint molecule exploited by cancer cells to evade immune surveillance. Discovered as part of the MARVEL domain-containing protein family, Cmtm6 interacts with PD-L1 to prevent its lysosomal degradation, thereby enhancing its immunosuppressive function in the tumor microenvironment. Antibodies targeting Cmtm6 have emerged as valuable tools to study this regulatory mechanism, offering insights into PD-L1 dynamics and potential therapeutic strategies. These antibodies are commonly used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect Cmtm6 expression in cell lines, tissues, or tumor samples. Research leveraging Cmtm6 antibodies has highlighted its role in cancer immunology, particularly in modulating anti-tumor immune responses. By disrupting Cmtm6-PD-L1 interactions, scientists aim to develop approaches to reduce PD-L1-mediated immune evasion, potentially enhancing the efficacy of cancer immunotherapies like anti-PD-1/PD-L1 treatments. Cmtm6 antibodies also serve as diagnostic tools to explore correlations between Cmtm6 expression levels, PD-L1 status, and clinical outcomes in various cancers.